ACN - Company News

Press Releases


Wednesday, February 19, 2020

AIM ImmunoTech (AIM) 公司向股東發布有關安普利近對抗武漢新型冠狀病毒潛在作用的最新信息
AIM ImmunoTech公司 (NYSE-American交易代碼: AIM) 是一家專注於研究和開發治療免疫疾病、病毒性疾病和多種癌症療法的免疫製藥公司。今天公司向股東提交了關於使用安普利近治療新型冠狀病毒，並將其用於疫苗研發的最新信息。 more info >>

AIM ImmunoTech(AIM)公司向股东发布有关安普利近对抗武汉新型冠状病毒潜在作用的最新信息
AIM ImmunoTech公司 (NYSE-American: AIM) 是一家专注于研究和开发治疗免疫疾病、病毒性疾病和多种癌症疗法的免疫制药公司。今天公司向股东提交了关于使用安普利近治疗新型冠状病毒，并将其用于疫苗研发的最新信息。 more info >>

Tuesday, February 11, 2020

AIM ImmunoTech提交了三項有關安普利近(R) 的臨時專利申請，以用於對抗類似SARS的武漢2019年新型冠狀病毒
AIM ImmunoTech公司（NYSE-American交易代碼：AIM）今天宣布提交了三份臨時專利申請，涉及其候選藥物安普利近，這是公司加入全球衛生界抗擊致命的武漢冠狀病毒的努力，該病毒迄今為止已經感染了大約40000人，有近千人死亡，主要集中在中國。 more info >>

AIM ImmunoTech提交了三项有关安普利近(R) 的临时专利申请，以用于对抗类似SARS的武汉2019年新型冠状病毒
AIM ImmunoTech公司（NYSE-American交易代码：AIM）今天宣布提交了三份临时专利申请，涉及其候选药物安普利近，这是公司加入全球卫生界抗击致命的武汉冠状病毒的努力，该病毒迄今为止已经感染了大约40000人，有近千人死亡，主要集中在中国。 more info >>

AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus
AIM ImmunoTech Inc. (NYSE American:AIM) today announced the filing of three provisional patent applications related to its drug candidate Ampligen in the company's efforts toward joining the global health community in the fight against the deadly Wuhan coronavirus that has so far infected approximately 40,000 people and killed almost one thousand, primarily in China. more info >>


1 2 3 4

Latest Press Releases

Fujitsu-sponsored professional golfer Ayaka Furue victorious in the Amundi Evian Championship Jul 16, 2024 23:26 JST

Best BLUETTI Prime Day Deals on Portable Power Stations and Solar Generators Jul 16, 2024 22:00 HKT/SGT

Lexaria Preparing For Strategic Growth Jul 16, 2024 21:20 HKT/SGT

'Alamein Festival' Launches Exciting Second Edition for 2024 Jul 16, 2024 21:00 HKT/SGT

China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating Jul 16, 2024 21:00: JST

China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating Jul 16, 2024 20:00 HKT/SGT

How Artificial Intelligence Can Help Give Your Business a Boost Jul 16, 2024 19:30 HKT/SGT

U.S. Polo Assn. Proudly Partners with the 2024 Outsourcing Inc. Royal Charity Polo Cup Jul 16, 2024 19:00 HKT/SGT

Neste and Mitsubishi Corporation agree on strategic partnership to develop supply chains for renewable chemicals and plastics Jul 16, 2024 18:36 JST

NEC technology reliably measures sea levels from a greater distance Jul 16, 2024 17:45 JST

全球发展数字经济直播访谈会正式举办外方来华参会高级别代表走进东方甄选直播间 Jul 16, 2024 15:08 HKT/SGT

巨星傳奇(6683.HK)解禁後首個交易日收盤報10.4港元升幅達2.97% Jul 16, 2024 15:04 HKT/SGT

巨星传奇(6683.HK)解禁后首个交易日: 收盘报10.4港元升幅达2.97% Jul 16, 2024 14:58 HKT/SGT

全球發展數字經濟直播訪談會正式舉辦外方來華參會高級別代表走進東方甄選直播間 Jul 16, 2024 14:25 HKT/SGT

Fujitsu and Cohere launch strategic partnership and joint development to provide generative AI for enterprises Jul 16, 2024 15:13 JST


More News >>


Home \| About us \| Services \| Partners \| Events \| Login \| Contact us \| Cookies Policy \| Privacy Policy \| Disclaimer \| Terms of Use \| RSS

US: +1 214 890 4418 \| China: +86 181 2376 3721 \| Hong Kong: +852 8192 4922 \| Singapore: +65 6549 7068 \| Tokyo: +81 3 6859 8575